Pharmacoepidemiology (third Edition)

Content: Chapter 1 What is Pharmacoepidemiology? (pages 1–15): Brian L. StromChapter 2 Study Designs Available for Pharmacoepidemiology Studies (pages 17–29): Brian L. StromChapter 3 Sample Size Considerations for Pharmacoepidemiology Studies (pages 31–39): Brian L. StromChapter 4 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies (pages 41–62): Patricia McGettigan, David A. Henry and Sean HennessyChapter 5 When Should One Perform Pharmacoepidemiology Studies? (pages 63–71): Brian L. StromChapter 6 The Public Health, the University, and Pharmacoepidemiology (pages 73–89): Paul D. Stolley and Joan?Ramon LaporteChapter 7 A View From Industry (pages 91–108): Dale B. Glasser and Gretchen S. DieckChapter 8 A View From Regulatory Agencies (pages 109–124): David J. Graham, Patrick C. Waller and Xavier KurzChapter 9 A View From a US Courtroom (pages 125–148): James R. Ruger and Sidney H. WilligChapter 10 Spontaneous Reporting in the United States (pages 149–174): Dianne L. Kennedy, Stephen A. Goldman and Ralph B. LillieChapter 11 Spontaneous Reporting Systems Outside the US (pages 175–192): Bengt?Erik Wiholm, Sten Olsson, Nicholas Moore and Patrick WallerChapter 12 Intensive Hospital?based Cohort Studies (pages 193–207): Keith Beard and David H. LawsonChapter 13 Case–Control Surveillance (pages 209–230): Samuel ShapiroChapter 14 Prescription?event Monitoring (pages 231–246): Ronald D. MannChapter 15 Group Health Cooperative of Puget Sound (pages 247–262): Kathleen W. Saunders, Robert L. Davis and Andy StergachisChapter 16 Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division (pages 263–283): Gary D. Friedman, Laurel A. Habel, Myde Boles and Bentson H. McFarlandChapter 17 Harvard Pilgrim Health Care/Harvard Vanguard Medical Associates (pages 285–293): K. Arnold Chan and Richard PlattChapter 18 UnitedHealth Group (pages 295–305): Deborah Shatin, Carole Drinkard and Andy StergachisChapter 19 Medicaid Databases (pages 307–324): Jeffrey L. Carson, Wayne A. Ray and Brian L. StromChapter 20 Health Databases in Saskatchewan (pages 325–345): Winanne Downey, Patricia Beck, Mary McNutt, Mary Rose Stang, William Osei and Jim NicholChapter 21 Automated Pharmacy Record Linkage in The Netherlands (pages 347–360): Hubert G. Leufkens and John UrquhartChapter 22 The Tayside Medicines Monitoring Unit (MEMO) (pages 361–374): Josie M.M. Evans and Thomas M. MacdonaldChapter 23 The UK General Practice Research Database (pages 375–385): Luis Alberto Garcia Rodriguez, Susanne Perez?Gutthann and Susan JickChapter 24 Other Approaches to Pharmacoepidemiology Studies (pages 387–399): Brian L. StromChapter 25 How Should One Perform Pharmacoepidemiology Studies? Choosing Among the Available Alternatives (pages 401–413): Brian L. StromChapter 26 Bioethical Issues in Pharmacoepidemiology Research (pages 415–431): David Casarett, Jason Karlawish, Elizabeth Andrews and Arthur CaplanChapter 27 National Medicinal Drug Policies: their Relationship to Pharmacoepidemiology (pages 433–447): Suzanne Hill and David A. HenryChapter 28 Premarketing Applications of Pharmacoepidemiology (pages 449–462): Harry A. GuessChapter 29 Studies of Drug Utilization (pages 463–481): David Lee and Ulf BergmanChapter 30 Evaluating and Improving Physician Prescribing (pages 483–503): Stephen B. Soumerai, Sumit Majumdar and Helene L. LiptonChapter 31 Drug Utilization Review (pages 505–523): Sean Hennessy, Brian L. Strom, Helene L. Lipton and Stephen B. SoumeraiChapter 32 Determining Causation from Case Reports (pages 525–538): Judith K. JonesChapter 33 The Use of Randomized Controlled Trials for Pharmacoepidemiology Studies (pages 539–552): Samuel M. Lesko and Allen A. MitchellChapter 34 The Use of Pharmacoepidemiology to Study Beneficial Drug Effects (pages 553–572): Brian L. Strom and Kenneth L. MelmonChapter 35 Pharmacoeconomics: Economic Evaluation of Pharmaceuticals (pages 573–601): Kevin A. Schulman, Henry Glick, Daniel Polsky and John M. EisenbergChapter 36 Using Quality of Life Measurements in Pharmacoepidemiology Research (pages 603–613): Gordon H. Guyatt and Roman JaeschkeChapter 37 N?of?1 Randomized Clinical Trials in Pharmacoepidemiology (pages 615–631): Gordon H. Guyatt, Roman Jaeschke and Robin RobertsChapter 38 The Use of Meta?analysis in Pharmacoepidemiology (pages 633–659): Jesse A. BerlinChapter 39 Validity of Pharmacoepidemiology Drug and Diagnosis Data (pages 661–705): Suzanne L. West, Brian L. Strom and Charles PooleChapter 40 Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety (pages 707–732): Robert T. ChenChapter 41 Special Methodological Issues in Pharmacoepidemiology Studies of Devices (pages 733–747): Roselie A. BrightChapter 42 Special Considerations in Studies of Drug?induced Birth Defects (pages 749–763): Allen A. MitchellChapter 43 Bias and Confounding in Pharmacoepidemiology (pages 765–784): Jean?Paul Collet and Jean?Francois BoivinChapter 44 Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis (pages 785–805): Samy SuissaChapter 45 The Future of Pharmacoepidemiology (pages 807–816): Brian L. Strom This is a thoroughly revised edition of Brian Stroms classic textbook which continues both to reflect the rapid evolution of this new field and to help shape it. Reviews of previous editions of his celebrated textbook include: "The book is essential reading for anyone interested in pharmacoepidemiology." International Journal of Epidemiology "The Second Edition is an excellent textbook and a comprehensive reference which belongs in the library of every pharmaceutical manufacturer and regulator." European Journal of Public Health "Pharmacoepidemiology: Second Edition reflects the maturation of a profession. Strom himself was a major driving force in that maturation " Jacqueline S. Gardner, University of Washington, Seattle, USA While maintaining the popular layout and easy-to-read style that made these earlier editions so successful, this work has been thoroughly revised to reflect the continued development of the field.*Analysis of current issues within the field*Fair representation of issues from around the world*Contains extensive appendices, including a glossary of important terms and sample size tablesThe third edition of Pharmacoepidemiology is an outstanding and fully comprehensive textbook, which will be an essential resource for all interested in the fieldãin academia, in regulatory agencies, in industry and in the law The Third Edition of this successful book has been revised and updated to include the latest advances in the field. It incorporates new topics such as prescription event monitoring, general practice research database, and drug utilization review.* Provides an American and European perspective.* The authors are renowned in the field.